Applied BioCode (6598) - Total Liabilities

Latest as of September 2025: NT$343.23 Million TWD ≈ $10.81 Million USD

Based on the latest financial reports, Applied BioCode (6598) has total liabilities worth NT$343.23 Million TWD (≈ $10.81 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Applied BioCode asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Applied BioCode - Total Liabilities Trend (2012–2024)

This chart illustrates how Applied BioCode's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 6598 asset base.

Applied BioCode Competitors by Total Liabilities

The table below lists competitors of Applied BioCode ranked by their total liabilities.

Company	Country	Total Liabilities
EDAG Engineering Group AG XETRA:ED4	Germany	€557.07 Million
CareCloud, Inc. NASDAQ:CCLD	USA	$76.45 Million
IDREAMSKY TE+H. DL-0001 F:08IA	Germany	€1.98 Billion
Raonsecure Co. Ltd KQ:042510	Korea	₩20.77 Billion
Empress Royalty Corp V:EMPR	Canada	CA$7.23 Million
Taiwan Takisawa Technology Co Ltd TWO:6609	Taiwan	NT$1.05 Billion
Martin Midstream Partners LP NASDAQ:MMLP	USA	$592.86 Million
Purit Co. Ltd. KQ:445180	Korea	₩18.83 Billion

Liability Composition Analysis (2012–2024)

This chart breaks down Applied BioCode's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 6598 equity to assets ratio to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	7.96	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.50	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.33	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Applied BioCode's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Applied BioCode (2012–2024)

The table below shows the annual total liabilities of Applied BioCode from 2012 to 2024.

Year	Total Liabilities	Change
2024-12-31	NT$336.07 Million ≈ $10.59 Million	+1.16%
2023-12-31	NT$332.22 Million ≈ $10.47 Million	-16.19%
2022-12-31	NT$396.38 Million ≈ $12.49 Million	+241.68%
2021-12-31	NT$116.01 Million ≈ $3.65 Million	-17.27%
2020-12-31	NT$140.23 Million ≈ $4.42 Million	-25.55%
2019-12-31	NT$188.36 Million ≈ $5.93 Million	+131.55%
2018-12-31	NT$81.35 Million ≈ $2.56 Million	+34.89%
2017-12-31	NT$60.30 Million ≈ $1.90 Million	+17.84%
2016-12-31	NT$51.17 Million ≈ $1.61 Million	+25.81%
2015-12-31	NT$40.67 Million ≈ $1.28 Million	+4.37%
2014-12-31	NT$38.97 Million ≈ $1.23 Million	+64.93%
2013-12-31	NT$23.63 Million ≈ $744.47K	+18.18%
2012-12-31	NT$20.00 Million ≈ $629.95K	--

About Applied BioCode

TW:6598 Taiwan Medical Devices

Market Cap

$88.74 Million

NT$2.82 Billion TWD

Market Cap Rank

#19711 Global

#1128 in Taiwan

Share Price

NT$27.40

Change (1 day)

+0.92%

52-Week Range

NT$20.55 - NT$31.50

All Time High

NT$177.50